ABSTRACT An eight-month-old female infant with severe dengue disease, who was repeatedly given therapeutic paracetamol for severe dengue, developed fulminant liver failure with encephalopathy, gastrointestinal haemorrhage and severe coagulopathy. She responded to supportive measures and N-acetylcysteine infusion. This case highlights the potential danger of administering repeated therapeutic doses of paracetamol in childhood severe dengue disease with hepatitis.
INTRODUCTION
Dengue fever (DF) is a global health problem.
(1) While the main manifestation in severe dengue disease (SDD) is primarily haemorrhage, dengue hepatitis is an increasingly well-known complication of SDD. (2) (3) (4) In severe hepatitis, fulminant hepatic failure (FHF) has been reported. (5) (6) The new World Health Organization (WHO) guidelines for DF recommend the administration of paracetamol (PCM) for high fever if the patient is uncomfortable. (7) However, these guidelines do not specify whether PCM should be given in the presence of hepatitis.
We report the case of an eight-month-old infant with SDD who was given therapeutic doses of PCM for fever. The illness was complicated by FHF. This case highlights the risk of severe liver injury in children with acute dengue hepatitis who are given repeated therapeutic doses of PCM.
CASE REPORT
An eight-month-old female infant was referred for further management of SDD, encephalopathy, coagulopathy and hepatitis. Her fever had started 13 days ago. She was admitted four times a day for a total of seven days. On examination, the patient appeared ill, oedematous, jaundiced, pale and very drowsy.
There was a generalised petechial rash, hepatosplenomegaly, gross ascites and bilateral basal crepitations over both lungs.
Haematemesis and malaena were present. There was also generalised hypertonia and hyperreflexia of all four limbs (hepatic encephalopathy grade III). 
DISCUS SION
FHF due to PCM overdose may be due to either a single large overdose or cumulative, multiple overdoses. (10, 11) The latter has been increasingly recognised as an important cause of FHF due to PCM overdose. (11) In a recent Australian and New Zealand guidelines for the management of PCM poisoning, a single dose of 200 mg/kg or more of PCM ingestion over a period of less than eight hours in children younger than six years old is considered likely to be associated with hepatic injury. (9) For those with repeated supratherapeutic ingestion, the doses are considerably lower, depending on the duration of ingestion. (9) However, the guidelines did not specify the dose that may possibly be associated with liver injury in children with pre-existing liver conditions. (9) Mild to moderate hepatitis is common in dengue, with its occurrence reported in 71% of children with dengue. Severe hepatitis (serum ALT > 300 IU/L) was noted in 15%. (4) The mortality rate of children with severe hepatitis in dengue was 67%. (4) Hence, hepatic involvement should be suspected in all patients, not only in those with DF, but possibly also in those with other viral or fulminant bacterial infections. Liver functions should be determined early, and in cases of prolonged fever, at regular intervals.
Our patient had clinical evidence of severe dengue with supportive dengue serology. During the course of her illness, she was given repeated therapeutic doses of PCM for one week.
Her serum PCM level was within the toxic range. Arguably, it is difficult to ascertain whether repeated administration of PCM in this patient ultimately resulted in FHF, as both severe dengue and repeated PCM administration can lead to hepatic injury.
There have not been many case reports on the effect of repeated PCM administration in therapeutic doses and its effect on liver function in patients with SDD, although some authors have advised checking for liver enzymes profile before administration of PCM in patients suspected of SDD. (12) There have been evidences, however, both in vitro and in vivo, that the metabolism of PCM is reduced in patients with hepatitis. (13, 14) Although at present, there is no study on the metabolism of PCM in cases of dengue complicated by concomitant hepatitis, it is likely that the result may be significant. The new WHO guidelines on DF allows PCM to be prescribed to relieve discomfort from fever.
However, there is no clear guideline on the regular use of PCM In this aspect, WHO's guidelines on dengue should also be updated to clarify the indications, dosing levels, duration and a safe antipyretic alternative for children with DF.
Although the prognosis of FHF secondary to PCM is generally quite favourable with a spontaneous recovery rate of 94%, patients with grade III encephalopathy have a recovery rate of only 33%. (10) In conclusion, in our report of a young infant with dengue haemorrhagic fever complicated by FHF, we suggest caution in the administration of repeated therapeutic doses of PCM in children with dengue or other medical conditions where the metabolism of PCM could be impaired.
